GT Biopharma (FRA:OXIA) ROCE %: -166.68% (As of Mar. 2026)


FRA:OXIA GT Biopharma Inc FRA:OXIA
21 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma ROCE %?

GT Biopharma FRA:OXIA 21 ROCE % is -166.68% as of Mar. 2026. GuruFocus rates FRA:OXIA with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GT Biopharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -166.68%.

GT Biopharma  (FRA:OXIA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GT Biopharma ROCE % Related Terms

GT Biopharma ROCE % Historical Data

* Premium members only.

The historical data trend for GT Biopharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma ROCE % Chart

GT Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -129.10 -75.26 -477.77 -1,439.59

GT Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -320.88 -342.31 -1,949.70 -166.68
FRA:OXIA
21GF Score
GT Biopharma Inc FRA:OXIA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma ROCE % Calculation

GT Biopharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-24.106/( ( (4.042 - 5.636) + (6.923 - 1.98) )/ 2 )
=-24.106/( (-1.594+4.943)/ 2 )
=-24.106/1.6745
=-1,439.59 %

GT Biopharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-9.584/( ( (6.923 - 1.98) + (8.647 - 2.09) )/ 2 )
=-9.584/( ( 4.943 + 6.557 )/ 2 )
=-9.584/5.75
=-166.68 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -166.68% mean?
GT Biopharma (FRA:OXIA) has a ROCE % of -166.68% as of Mar. 2026.
Is GT Biopharma's ROCE % too high?
GT Biopharma's current ROCE % is -166.68%. Overall, GT Biopharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's ROCE % compare to CTXR and HIND?
GT Biopharma's ROCE % of -166.68% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. GT Biopharma's current ROCE % is -166.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (FRA:OXIA) has a current ROCE % of -166.68%. The current ROCE % is -166.68%. GT Biopharma's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For GT Biopharma (FRA:OXIA), the current ROCE % is -166.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
21GF Score

Get the complete analysis for FRA:OXIA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price